OliX Pharmaceuticals, a gene therapy developer, recorded a daily limit up on the 10th after news that it signed a global ...
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...
Zacks.com on MSN4d
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItFailed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...
Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...
Novo Nordisk, the Danish pharmaceutical giant that makes ... intervention,” the company said in its submission. Eli Lilly, the American company that makes a rival weight-loss drug called ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Korea Joongang Daily on MSN4d
Olix, Eli Lilly to develop liver disease drug under $630 million dealOlix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback